Table 1.
Comparison of antibody and seroconversion response of treatment subgroups versus control and within the same subgroup
| Treatment subgroup | Timepoint-2 (versus control) |
Timepoint-3 (versus control) |
Timepoint-3 versus timepoint-2 |
|||||
|---|---|---|---|---|---|---|---|---|
| Evaluable, n (%) | Median IgG titer (IQR), AU/ml [P value] | Seroconversion ratea, n (%) [P value] | Evaluable, n (%) | Median IgG titer (IQR), AU/ml [P value] | Seroconversion ratea, n (%) [P value] | Median IgG titer (P value) | Seroconversion rate (P value) | |
| Control (N = 86) | 86 (100) | 144 (26-318) | 60 (69.8) | 79 (91.8) | 2096 (513-6021) | 72 (91.1) | <0.001 | <0.001 |
| Cytotoxic therapies | ||||||||
| Antimicrotubule agents (N = 28) | 26 (92.9) | 68 (9-318) [0.23] | 13 (50) [0.06] | 25 (89.3) | 1288 (729-8133) [0.66] | 22 (88) [0.65] | <0.001 | 0.003 |
| Topoisomerase inhibitors (N = 17) | 15 (88.2) | 24 (9-76) [0.05] | 5 (33.3) [0.006] | 14 (82.4) | 199 (34-3520) [0.018] | 10 (71.4) [0.03] | 0.035 | 0.040 |
| Antimetabolites (N = 44) | 44 (100) | 24 (9-143) [0.003] | 17 (38.6) [<0.001] | 41 (93.2) | 1530 (207-3872) [0.20] | 38 (92.7) [0.75] | <0.001 | <0.001 |
| Alkylating agents (N = 52) | 51 (98) | 39 (11-163) [0.005] | 21 (41.2) [<0.001] | 47 (90.3) | 882 (179-2240) [0.003] | 42 (87.5) [0.51] | <0.001 | <0.001 |
| Multiple cytotoxic agents (N = 68) | 66 (97.1) | 28 (11-137) [0.002] | 24 (36.4) [<0.001] | 61 (89.7) | 866 (157-1998) [0.003] | 52 (85.2) [0.27] | <0.001 | <0.001 |
| Biological therapies | ||||||||
| Hormonal therapy (N = 15) | 15 (100) | 82 (13-444) [0.53] | 9 (60) [0.44] | 13 (86.7) | 5583 (565-10 726) [0.27] | 12 (92.3) [0.82] | 0.001 | 0.038 |
| Immune checkpoint inhibitors (N = 32) | 29 (90.6) | 78 (18-185) [0.22] | 16 (55.2) [0.15] | 29 (90 .6) | 1436 (151-3480) [0.19] | 28 (96.6) [0.32] | <0.001 | <0.001 |
| PARP inhibitors (N = 6) | 6 (100) | 100 (9-447) [0.58] | 3 (50) [0.31] | 5 (83.3) | 6905 (670-8634) [0.56] | 5 (100) [0.52] | 0.043 | <0.001 |
| TKIs (N = 29) | 28 (96.5) | 30 (12-138) [0.036] | 12 (42.9) [0.01] | 27 (93.1) | 1443 (284-5524) [0.47] | 24 (88.9) [0.72] | <0.001 | <0.001 |
| Monoclonal antibodies (N = 30) | 29 (96.6) | 144 (66-658) [0.30] | 24 (82.8) [0.17] | 29 (96.6) | 2419 (1487-8466) [0.19] | 27 (93.1) [0.74] | <0.001 | 0.018 |
| CDK4/6 inhibitors (N = 23) | 23 (100) | 149 (24-858) [0.43] | 16 (69.6) [0.98] | 23 (100) | 3094 (1757-9385) [0.11] | 23 (100) [0.45] | <0.001 | 0.016 |
| mTOR inhibitors (N = 4) | 4 (100) | 11 (1-472) [0.20] | 1 (25) [0.06] | 4 (100) | 72 (37-1839) [0.047] | 2 (50) [0.009] | 0.068 | 0.34 |
AU, arbitrary unit; CDK, cyclin-dependent kinase; IgG, immunoglobulin G; IQR, interquartile range; mTOR, mechanistic target of rapamycin; PARP, poly (ADP-ribose) polymerase; TKIs, tyrosine kinase inhibitors.
a
Seroconversion response rates at cut-off of 50 AU/ml.